Steven Deeks, MD
Biography
Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment. He is also now leading a large program focused on the pathogenesis and treatment of Long COVID.
Dr. Deeks has published over 650 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants and is the contact principal investigator of DARE (the Delaney AIDS Research Enterprise), an NIH-funded international collaboration aimed at developing therapeutic interventions to cure HIV infection. He recently directed the amfAR Institute for HIV Cure Research. In early 2020, he leveraged his HIV research program to construct the “Long-term Impact of Infection with Novel Coronavirus (LIINC)” cohort, which is now supporting dozens of studies addressing the impact of SARS-CoV-2 on health.
Dr. Deeks is a member of the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP). He serves on the scientific advisory board for Science Translational Medicine and is the editor-in-chief of Current Opinion in HIV and AIDS. Based on a recent study conducted at Stanford, he is among the top 0.01% of all scientists, based on citations, adjusted for authorship position and impact, and has been listed by Clarivite as one of the world's most cited scientists for the past several years. In 2022, he received the Lifetime Achievement in Mentoring Award from UCSF.
In addition to his translational and clinical. investigation, Dr. Deeks maintains a primary care clinic for people living with HIV.
Displaying 526 - 550 of 668
- Marconi V, Bonhoeffer S, Paredes R, Lu J, Hoh R, Martin JN, Deeks SG, Kuritzkes DR. Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. . 2008 Aug 15; 48(5):572-6.
- Probasco JC, Spudich SS, Critchfield J, Lee E, Lollo N, Deeks SG, Price RW. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. Neurology. 2008 Aug 12; 71(7):521-4.
- Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, Bangsberg DR. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008 Jul 30; 3(7):e2783.
- Deeks SG. Transmitted minority drug-resistant HIV variants: a new epidemic? PLoS Med. 2008 Jul 29; 5(7):e164.
- Schweneker M, Favre D, Martin JN, Deeks SG, McCune JM. HIV-induced changes in T cell signaling pathways. J Immunol. 2008 May 15; 180(10):6490-500.
- Wang P, Huang L, Davis JL, Swartzman A, Roth B, Stone J, Wu AH. A hydrophilic-interaction chromatography tandem mass spectrometry method for quantitation of serum s-adenosylmethionine in patients infected with human immunodeficiency virus. Clin Chim Acta. 2008 Oct; 396(1-2):86-8.
- Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):544-52.http://www.ncbi.nlm.nih.gov/pubmed/8301319
- Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med. 2008 Apr; 14(4):413-20.
- Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol. 2008 Jun; 82(11):5398-407.http://www.ncbi.nlm.nih.gov/pubmed/1447577
- Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SG. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther. 2008; 13(3):369-74.
- Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008 Jan 01; 197(1):126-33.http://www.ncbi.nlm.nih.gov/pubmed/1919607
- Barker E, Martinson J, Brooks C, Landay A, Deeks S. Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS. 2007 Nov 12; 21(17):2363-5.
- Petersen ML, Deeks SG, van der Laan MJ. Individualized treatment rules: generating candidate clinical trials. Stat Med. 2007 Nov 10; 26(25):4578-601.
- Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, Miura T, Hecht FM, Mamtani M, Pereyra F, Marconi V, Mangano A, Sen L, Bologna R, Clark RA, Anderson SA, Delmar J, O'Connell RJ, Lloyd A, Martin J, Ahuja SS, Agan BK, Walker BD, Deeks SG, Ahuja SK. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol. 2007 Dec; 8(12):1324-36.
- Petersen ML, Deeks SG, Martin JN, van der Laan MJ. History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol. 2007 Nov 01; 166(9):985-93.
- Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007 Sep; 27(3):406-16.
- Deeks SG. Protease inhibitors as immunomodulatory drugs for HIV infection. Clin Pharmacol Ther. 2007 Sep; 82(3):248-50.
- Owen RE, Sinclair E, Emu B, Heitman JW, Hirschkorn DF, Epling CL, Tan QX, Custer B, Harris JM, Jacobson MA, McCune JM, Martin JN, Hecht FM, Deeks SG, Norris PJ. Loss of T cell responses following long-term cryopreservation. J Immunol Methods. 2007 Sep 30; 326(1-2):93-115.http://www.ncbi.nlm.nih.gov/pubmed/1967349
- Karlsson AC, Chapman JM, Heiken BD, Hoh R, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF. Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. J Virol. 2007 Oct; 81(20):11543-8.
- Lederman MM, Miller V, Weller I, Deeks SG. A new approach for 'deep salvage' trials in advanced HIV infection. AIDS. 2007 Jul 31; 21(12):1503-6.
- Hatano H, Deeks SG. Drug resistant HIV. BMJ. 2007 Jun 2; 334(7604):1124-5.
- Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL, Phair J, Goedert JJ, Buchbinder S, Kirk GD, Telenti A, Connors M, O'Brien SJ, Walker BD, Parham P, Deeks SG, McVicar DW, Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. 2007 Jun; 39(6):733-40.
- Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May; 4(2):65-72.
- Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol. 2007 Apr; 81(7):3240-50.
- Kamya MR, Gasasira AF, Achan J, Mebrahtu T, Ruel T, Kekitiinwa A, Charlebois ED, Rosenthal PJ, Havlir D, Dorsey G. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007 Oct 01; 21(15):2059-66.